• Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet

Kombinasjonen av Opdivo og Yervoy øker langtidsoverlevelsen ved avansert melanom

Skrevet av Bo Karl Christensen 29. mai 2021. Publisert i Hudkreft

Immunterapiene Yervoy (ipilimumab) og Opdivo (nivolumab) øker overlevelsen betydelig hos pasienter med avansert melanom sammenliknet med Opdivo alene.

Les mer …

Nyheter fra ESMO

  • Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma Data support metronomic capecitabine as a potential adjuvant therapy for nasopharyngeal carcinoma 

    Created on: Jun 14, 2021 | 10:15 am
    Jun 14, 2021 | 10:15 am
  • Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab A novel checkpoint inhibitors combination of nivolumab plus relatlimab validate dual LAG-3 and PD-1 inhibition

    Created on: Jun 11, 2021 | 12:08 pm
    Jun 11, 2021 | 12:08 pm
  • EMA Recommends Extension of Indications for Daratumumab EMA Recommends Extension of Indications for Daratumumab New indications concern the treatment of patients with multiple myeloma and light chain amyloidosis

    Created on: Jun 10, 2021 | 14:23 pm
    Jun 10, 2021 | 14:23 pm
  • EMA Recommends Extension of Indications for Blinatumomab EMA Recommends Extension of Indications for Blinatumomab New indication concerns the treatment of paediatric patients with high-risk first relapsed Philadelphia chromosome negative CD19-positive B-precursor ALL

    Created on: Jun 9, 2021 | 09:10 am
    Jun 9, 2021 | 09:10 am
  • NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought Findings from the eNRGy1 global multicentre registry

    Created on: Jun 8, 2021 | 10:12 am
    Jun 8, 2021 | 10:12 am

Siste nytt om lungekreft

Keytruda viser lovende data for behandling av inoperabel lungekreft

Etter fem år: Alectinib er ikke bedre enn crizotinib mot ALK+ lungekreft

Libtayo like før EU-godkjennelse mot både avansert lungekreft og hudkreft

Tecentriq godkjent i EU som førstelinjebehandling mot ikke-småcellet lungekreft med høy PD-L1

Powered by Warp Theme Framework
  • Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet